After stumbling badly in its initial efforts to tightly control production of Tamiflu, an antiviral important in containing possible human bird-flu pandemic, Roche is now attempting to brighten its tarnished image with secret negotiations for sub-licenses. These licenses, while they might speed stockpiles for rich countries and pad profits for Roche, will do little to ensure access for poor people in developing countries.
